相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Activation of the renal GLP-1R leads to expression of Ren1 in the renal vascular tree
Katrine Dahl Bjornholm et al.
ENDOCRINOLOGY DIABETES & METABOLISM (2021)
Glucagon-like peptide-1 alleviates diabetic kidney disease through activation of autophagy by regulating AMP-activated protein kinase-mammalian target of rapamycin pathway
Shuangli Yang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2020)
Liraglutide protects against high-fat diet-induced kidney injury by ameliorating apoptosis
Riying Liang et al.
ENDOCRINE CONNECTIONS (2020)
GLP-1-induced renal vasodilation in rodents depends exclusively on the known GLP-1 receptor and is lost in prehypertensive rats
Elisa P. Jensen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2020)
Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys
Habib Yaribeygi et al.
DRUG DISCOVERY TODAY (2019)
Antioxidative potential of antidiabetic agents: A possible protective mechanism against vascular complications in diabetic patients
Habib Yaribeygi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways
Habib Yaribeygi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
A review of the anti-inflammatory properties of antidiabetic agents providing protective effects against vascular complications in diabetes
Habib Yaribeygi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Interleukin-18 and diabetic nephropathy: A review
Habib Yaribeygi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Sodium-glucose cotransporter inhibitors and oxidative stress: An update
Habib Yaribeygi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
The role of nitric oxide signaling in renoprotective effects of hydrogen sulfide against chronic kidney disease in rats: Involvement of oxidative stress, autophagy and apoptosis
Mohammad Khabbaz Shirazi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Dipeptidyl Peptidase 4 Inhibition Ameliorates Chronic Kidney Disease in a Model of Salt-Dependent Hypertension
Donato Cappetta et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2019)
An experimental study of exenatide effects on renal injury in diabetic rats
Xiaodong Wang et al.
ACTA CIRURGICA BRASILEIRA (2019)
Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling
Yoon Sin Oh et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Crocin improves renal function by declining Nox-4, IL-18, and p53 expression levels in an experimental model of diabetic nephropathy
Habib Yaribeygi et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
Fenofibrate improves renal function by amelioration of NOX-4, IL-18, and p53 expression in an experimental model of diabetic nephropathy
Habib Yaribeygi et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
Oxidative stress induces renal failure: A review of possible molecular pathways
Habib Yaribeygi et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
The glucagon-like peptide-1 (GLP-1) analog liraglutide attenuates renal fibrosis
Ya-Kun Li et al.
PHARMACOLOGICAL RESEARCH (2018)
GLP-1 receptor agonist ameliorates obesity-induced chronic kidney injury via restoring renal metabolism homeostasis
Chengshi Wang et al.
PLOS ONE (2018)
Glucagon-Like Peptide-1 Mediates the Protective Effect of the Dipeptidyl Peptidase IV Inhibitor on Renal Fibrosis via Reducing the Phenotypic Conversion of Renal Microvascular Cells in Monocrotaline-Treated Rats
Jian Xu et al.
BIOMED RESEARCH INTERNATIONAL (2018)
Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the US Population
Kristina S. Boye et al.
DIABETES THERAPY (2018)
Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the US Population
Kristina S. Boye et al.
DIABETES THERAPY (2018)
Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
Marcel H. A. Muskiet et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators
Gaojie Song et al.
NATURE (2017)
Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation
Cristina Barale et al.
THROMBOSIS AND HAEMOSTASIS (2017)
EX4 stabilizes and activates Nrf2 via PKCδ, contributing to the prevention of oxidative stress-induced pancreatic beta cell damage
Mi-Hwi Kim et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2017)
Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway
Esther Civantos et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2017)
Renal hemodynamic effects of glucagon-ike peptide-1 agonist are mediated by nitric oxide but not prostaglandin
Scott C. Thomson et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2017)
The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory
Gemma Pujadas et al.
ENDOCRINE (2017)
IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040
K. Ogurtsova et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2017)
The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes
Merlin C. Thomas
DIABETES & METABOLISM (2017)
Renal Protective Effect of DPP-4 Inhibitors in Type 2 Diabetes Mellitus Patients: A Cohort Study
Young-Gun Kim et al.
JOURNAL OF DIABETES RESEARCH (2016)
A Hydrogen-Bonded Polar Network in the Core of the Glucagon-Like Peptide-1 Receptor Is a Fulcrum for Biased Agonism: Lessons from Class B Crystal Structures
Denise Wootten et al.
MOLECULAR PHARMACOLOGY (2016)
Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
Sen Shi et al.
FIBROGENESIS & TISSUE REPAIR (2016)
Sitagliptin attenuates transient cerebral ischemia/reperfusion injury in diabetic rats: Implication of the oxidative-inflammatory-apoptotic pathway
Ayman E. El-Sahar et al.
LIFE SCIENCES (2015)
DPP-4 inhibitor sitagliptin prevents inflammation and oxidative stress of heart and kidney in two kidney and one clip (2K1C) rats
Md. Ashraful Alam et al.
DIABETOLOGY & METABOLIC SYNDROME (2015)
High prevalence of chronic kidney disease in Finnish patients with type 2 diabetes treated in primary care
Kaj Metsarinne et al.
PRIMARY CARE DIABETES (2015)
Exenatide induces aortic vasodilation increasing hydrogen sulphide, carbon monoxide and nitric oxide production
Eszter Selley et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen
Keizo Kanasaki et al.
DIABETES (2014)
The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems
J. Seufert et al.
DIABETES OBESITY & METABOLISM (2014)
DPP-4 inhibitors: pharmacological differences and their clinical implications
Antonio Ceriello et al.
EXPERT OPINION ON DRUG SAFETY (2014)
Sitagliptin Prevents Inflammation and Apoptotic Cell Death in the Kidney of Type 2 Diabetic Animals
Catarina Marques et al.
MEDIATORS OF INFLAMMATION (2014)
Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus
Hiroko Mori et al.
JOURNAL OF DIABETES INVESTIGATION (2014)
Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings
J. J. Holst et al.
DIABETES OBESITY & METABOLISM (2013)
Cardioprotective effects of exenatide against oxidative stress-induced injury
Guanglei Chang et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2013)
A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients
Noriko Satoh-Asahara et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2013)
Molecular mechanisms in the pathogenesis of diabetic nephropathy: An update
Mandeep Kumar Arora et al.
VASCULAR PHARMACOLOGY (2013)
Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria
Martin Haluzik et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2013)
Effects of glucagon-like peptide-1 receptor agonists on renal function
Theodosios D. Filippatos et al.
WORLD JOURNAL OF DIABETES (2013)
The structure and function of the glucagon-like peptide-1 receptor and its ligands
Dan Donnelly
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease
Ai-li Sun et al.
DIABETES & VASCULAR DISEASE RESEARCH (2012)
Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis
C. F. Deacon et al.
DIABETES OBESITY & METABOLISM (2012)
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Juris J. Meier
NATURE REVIEWS ENDOCRINOLOGY (2012)
Effect of Exenatide on Inflammatory and Oxidative Stress Markers in Patients with Type 2 Diabetes Mellitus
Jin-dan Wu et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2011)
Modulation of the Glucagon-Like Peptide-1 Receptor Signaling by Naturally Occurring and Synthetic Flavonoids
Denise Wootten et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Cellular and molecular mechanisms of renal fibrosis
Youhua Liu
NATURE REVIEWS NEPHROLOGY (2011)
One-year treatment with exenatide vs. Insulin Glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress
Mathijs C. Bunck et al.
ATHEROSCLEROSIS (2010)
Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor
Christina Rye Underwood et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat)
Liliana Ferreira et al.
MEDIATORS OF INFLAMMATION (2010)
Exaggerated liver injury induced by renal ischemia reperfusion in diabetes: Effect of exenatide
JitendraD Vaghasiya et al.
Saudi Journal of Gastroenterology (2010)
Anti-apoptotic Action of Exendin-4 in INS-1 Beta Cells: Comparative Protein Pattern Analysis of Isolated Mitochondria
D. Tews et al.
HORMONE AND METABOLIC RESEARCH (2009)
Cellular and molecular mechanisms of fibrosis
T. A. Wynn
JOURNAL OF PATHOLOGY (2008)
Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-β, and fibronectin with concomitant increase in nitric oxide bioavailability
Ming-Sheng Zhou et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2008)
DPP-4 inhibitors
Bo Ahren
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size
Karen A. Scott et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2007)
Biology of incretins: GLP-1 and GIP
Laurie L. Baggio et al.
GASTROENTEROLOGY (2007)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Endothelial nitric oxide synthase in vascular disease -: From marvel to menace
U Förstermann et al.
CIRCULATION (2006)
Renal fibrosis: New insights into the pathogenesis and therapeutics
YH Liu
KIDNEY INTERNATIONAL (2006)
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice
XK Ding et al.
HEPATOLOGY (2006)
Epac: A new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell
GG Holz
DIABETES (2004)
分享论文
